Setting a New Standard in MRD Detection: Achieving Parts-per-Million Level Sensitivity with Inocras Whole Genome Platform and Ultima ppmSeq™

Whole genome sequencing (WGS) has transformed the landscape of genomic testing, offering unmatched precision in identifying complex mutations across cancer and rare diseases. By integrating WGS with advanced bioinformatics, Inocras provides a comprehensive genomic view through paired somatic/germline testing (CancerVision) and germline testing (RareVision), delivering clinically actionable insights. In addition to comprehensive cancer profiling, Inocras's MRDVision employs the WGS approach for ultra-sensitive, panel-free detection of minimal residual disease (MRD) at the parts-per-million (ppm) level. This workshop explores the clinical integration of Inocras' WGS technology for cancer profiling and MRD detection, demonstrating how our solutions provide actionable insights with broad clinical impact while achieving fast turnaround time and affordability.